Clinical Research Global Compliance Just Got Easier - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Clinical Research Global Compliance Just Got Easier

Source: Company News Release

Schulman Associates IRB, Inc. and Falcon Consulting Group, LLC announced today that they have formed a joint venture, Provision Research Compliance Services. Provision offers global consultancy services for the development and implementation of Good Clinical Practice (GCP) and Human Research Protection (HRP) procedural standards and programs for the conduct of clinical research studies.

"There has never been a collaboration of GCP and HRP industry leaders specifically focused on meeting the compliance needs of research institutions around the world," said Schulman Associates IRB President, Chief Executive Officer and Institutional Official Michael Woods. "Provision makes it easier for institutions to achieve their compliance goals and to engage in global development programs. It also helps study sponsors follow a simpler path to consistent compliance practices across a global network of research institutions. Global compliance just got easier."

Today, clinical trials are global, involving potentially hundreds of sites in a dozen or more countries. Pharmaceutical, biopharmaceutical and medical device sponsors need consistent quality and ethical standards for human subject protection and compliance to minimize regulatory risk.

Consistency is key to making a clinical trial as meaningful as possible, and the data as useful as possible. Meeting global compliance standards has been challenging because of outsourcing and the increasing complexity of the research. The approach to global compliance has often been very fragmented, and Provision offers a more comprehensive solution to achieving global compliance standards.

Enhanced Compliance for Integrity and Quality

The pharmaceutical, biopharmaceutical and medical device industries rely heavily on third parties to assist in the advancement of clinical research programs. Global contract research organizations (CROs) provide fundamental services for protocol development, study conduct, clinical program management, pharmacovigilance and data management, all directed to regulatory submissions and product approvals. Academic research institutions in locations around the world are responsible for study conduct and subject recruitment, according to the protocol as well as International Conference on Harmonisation (ICH) GCP standards and guidelines.

While there are regulations and local customs unique to countries and regions around the world, research institutions still strive to conduct research consistent with ICH GCP standards. An alignment of GCP and HRP practices provides the essential regulatory compliance and significantly improves performance of clinical studies.

Experienced Research Compliance Leaders

While Provision Research Compliance Services is new, the two organizations behind Provision are industry leaders, with proven expertise in clinical quality assurance and human research protection.

Provision provides services that combine the extensive GCP quality assurance expertise of Falcon Consulting Group with the HRP expertise of Schulman Associates IRB. The new joint venture provides comprehensive solutions to improve overall quality standards for clinical studies and data integrity, and maximizes the protection of human research subjects. Provision's services are available in more than 30 countries.

By improving GCP quality assurance and human research protection programs, clinical study data becomes more reliable and human subject protection is strengthened. This leads to more compliant submissions and more rapid approvals for patient therapies.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here